ATELVIA (risedronate sodium)
Atelvia is a delayed-release medication used for postmenopausal women who have osteoporosis. It helps patients with this condition by reducing the risk of both spinal and other types of bone fractures. Because the ideal length of time to take this drug is not yet known, healthcare providers regularly re-evaluate the need for continued use and may suggest stopping therapy after three to five years for those at low risk of fracture.
How ATELVIA Works
This drug works by binding to hydroxyapatite crystals within the bone to act as an antiresorptive agent. It specifically targets and inhibits osteoclasts, the cells responsible for breaking down bone tissue, which reduces the overall rate of bone turnover.
Details
- Status
- Prescription
- First Approved
- 2010-10-08
- Patent Cliff
- 2028
- Routes
- ORAL
- Dosage Forms
- TABLET, DELAYED RELEASE
ATELVIA Approval History
What ATELVIA Treats
1 indicationsATELVIA is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Osteoporosis
ATELVIA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ATELVIA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03208582 BAMES | SCH-2013 | Ph 2 | completed | Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta? |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ATELVIA FDA Label Details
Indications & Usage
FDA Label (PDF)ATELVIA is indicated for the treatment of Osteoporosis.
Pro Intelligence Preview
Deep insights for ATELVIA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2028
- • 3 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.